PASADENA, Calif., Nov. 20, 2020 /PRNewswire/ — A study published in the American Journal of Emergency Medicine this month reports on an assessment tool developed by Kaiser Permanente researchers and physicians that helps ensure patients get the right care, when they need it, by accurately predicting the probability that patients with COVID-19 symptoms will experience severe disease or even death.
“As the pandemic surges again across the country and hospitalizations are increasing, front-line physicians often must make quick decisions to hospitalize or discharge patients with COVID-19 symptoms,” said Adam Sharp, MD, an emergency medicine physician who also is a researcher for the Kaiser Permanente Southern California Department of Research & Evaluation. “We created a risk assessment that looks at many different patient variables that might predict a critical poor outcome — without any lab or diagnostic testing.”
The risk score is particularly helpful to physicians in making these decisions at the time of the emergency department visit, Dr. Sharp said.
The assessment tool, called the COVAS score because it looks at comorbidities, obesity, vital signs, age, and sex, has already been incorporated into the electronic health record system throughout Kaiser Permanente in Southern California, where it guides clinical decisions in emergency departments and urgent care centers. In this study, the COVAS score accurately predicted the probability of death or the need for critical respiratory care within 7 days for patients seen at Kaiser Permanente emergency departments in Southern California.
“I have used this tool successfully with my own patients in the emergency department and it helps provide necessary information to make informed decisions with patients,” Dr. Sharp said. “It can help to reassure low-risk patients, and alternatively can encourage those at high risk to receive hospital-based care that may speed their recovery.”
Researchers conducted a retrospective study of 26,600 emergency department visits by adults for symptoms suspicious for COVID-19 at 15 Kaiser Permanente hospitals in Southern California between March 1, 2020, to April 30, 2020, a period of time when substantial community spread of COVID-19 was prevalent in the region but immediate COVID-19 test results were not.
The results inform front-line health professionals and health systems about which patients with COVID-19 symptoms, which include fever, cough, difficulty breathing, and fatigue, are at greatest risk of death or respiratory decompensation that would require ventilation or high-flow oxygen.
Previous studies have focused on hospitalized patients, with little information about those treated outside of the inpatient setting. This work examines emergency department patients with suspected COVID-19 and provides helpful information to front-line physicians to inform care decisions, particularly during surges when hospital capacity can be limited.
About the Kaiser Permanente Southern California Department of Research & Evaluation
The Department of Research & Evaluation conducts high-quality, innovative research into disease etiology, prevention, treatment, and care delivery. Investigators conduct epidemiologic research, health services research, biostatistics research, and behavioral research as well as clinical trials. Major areas of study include chronic disease, infectious disease, cancer, drug safety and effectiveness, and maternal and child health. Headquartered in Pasadena, California, the department focuses on translating research to practice quickly to benefit the health and lives of Kaiser Permanente Southern California members and the general public. Visit kp.org/research.
About Kaiser Permanente
For 75 years, Kaiser Permanente has been committed to shaping the future of health and health care — and helping our members, patients, and communities experience more healthy years. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Since July 21, 1945, Kaiser Permanente’s mission has been to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 12.4 million members in 8 states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists, and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery, and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education, and the support of community health.
SOURCE Kaiser Permanente
Adverty is granted US patent for in-game ad viewability technology BrainImpression™
STOCKHOLM, Nov. 24, 2020 /PRNewswire/ — Adverty AB (publ) has been granted a patent by the United States Patent and Trademark Office for its in-game ad viewability technology BrainImpression™; a groundbreaking method for determining ad viewability and impressions within complex gaming environments. The patented invention is one of the core functionalities of Adverty’s leading in-game advertising platform.
Adverty, the leading in-game platform for advertisers, agencies and game developers, today announces the notice of allowance for its in-game ad viewability technology patent by the United States Patent and Trademark Office. The technology, called BrainImpression™, is a groundbreaking method for determining ad viewability and ad impressions, for example, when an advert is considered as seen by the user, within complex computer-generated graphical environments such as two-dimensional and three-dimensional games.
Viewability is one of the most important metrics in brand advertising and several renowned brands tend to exclude websites and other advertising media with low viewability in their media plans. To help advertisers understand and publishers define how to count an ad as seen, the media industry has established standards on how to measure web-based ad viewability. In regards to in-game advertising viewability, the industry is still at its infancy, with Adverty taking an active role in helping both IAB and third party ad verification leaders define these industry-wide, sought-after standards.
“Our patented in-game viewability algorithm outlines one of the core functionalities in our cutting-edge ad platform. We use our knowledge and innovation to help define appropriate viewability standards for in-game advertising – something that will benefit the media industry and heighten the acceptance of this new ad format amongst advertisers”, says Niklas Bakos, CEO and founder at Adverty.
The BrainImpression™ patent covers and protects a method of deciding if an advertisement, displayed in a gaming environment and shown on a display, has been seen by a user. The method of decision is based on the ad size, time in view and position on display for the user. Depending on the size of the ad on display, the ad is classified as seen after various time intervals, triggering an ad impression by the system.
Furthermore, the patent covers specific methods for adverts in the three-dimensional gaming space, where viewing angles and incidence angles towards the ad and the user display determine how well the ad is visible at any given time. For example, an ad unit viewed from the side is not detected as quickly, if at all, depending on its viewing angle, compared to an ad unit seen from a straight angle. Moreover, an advert placed in the center of the field of view is classified as seen faster than an ad closer to the periphery with a higher angle of incidence.
The BrainImpression™ patent application was filed in March 2017 at a time when Adverty focused on future gaming platforms such as Virtual, Augmented and Mixed Reality. Over the years, the focus has shifted towards mobile games, the largest and fastest growing gaming platform globally. Altogether, Adverty has established a leading cross-platform framework for unobtrusive, in-game brand and performance advertising, allowing brands to connect with new audiences in unique ways.
With the company’s fundamental mission in mind, the patent US 16/499.258 / US20200110262A1 covers head-mounted displays, such as Virtual Reality headsets, Augmented Reality headsets and smart glasses. A continuing application to protect the invention for other displays such as mobile phone, tablet and TV screens has been submitted to the United States Patent and Trademark Office.
For further information, please contact:
Niklas Bakos, CEO
Phone: +46 733 28 1110
E-mail: [email protected]
This information is information that Adverty AB (publ) is obliged to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on the 24th of November 2020.
Augment Partners AB, phone +46 8-505 65 172, act as certified advisor/mentor for the company at NGM Nordic SME.
Adverty, the leading in-game platform, delivers seamless advertising to connect brands and people through its revolutionary display advertising technology built for games. The platform offers true in-game ad inventory at scale and allows content creators to monetise the complete experience with unobtrusive, easy-to-integrate, immersive ads. Founded in 2016, Adverty has offices in Stockholm, London and Lviv and works with advertisers, agencies and developers to unlock audiences and gaming revenue streams. More information at www.adverty.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Adverty AB
Oslo, Los Angeles, Cidade do México e Budapeste estão empenhados na construção limpa para levar a indústria da construção a um futuro sustentável
Na C40’s Clean Construction Declaration os presidentes de câmara comprometem-se a revolucionar a indústria de construção global e a levá-la a um futuro mais sustentável para alcançar “uma vida próspera, resiliente e saudável para todos nas nossas cidades, especialmente nas comunidades mais vulneráveis”.
A indústria da construção é actualmente responsável por mais de 23% das emissões globais de gases com efeito de estufa e 30% do consumo global de recursos. “Business as usual” significaria um perigoso aumento da temperatura global de 3°C.
A declaração estabelece objectivos ousados e ambiciosos para o desenvolvimento dos edifícios e infra-estruturas do futuro com emissões líquidas zero:
- Reduzir as emissões em pelo menos 50% para todos os novos edifícios e renovações até 2030.
- Redução das emissões em pelo menos 50% de todos os projectos de infra-estruturas até 2030
- Aquisição e, se possível, utilização de maquinaria de construção exclusivamente livre de emissões a partir de 2025.
A obrigação de converter e modernizar os edifícios existentes tem um enorme potencial para criar novos empregos verdes, que são essenciais para uma recuperação equilibrada e amiga do ambiente a partir do Covid-19.
Os autarcas utilizarão o seu poder de compra para normalizar o equipamento de construção com emissões zero, exigir transparência e responsabilidade na cadeia de fornecimento, incorporar uma política de construção limpa nos procedimentos de concepção, aquisição e contratação e nos códigos de construção. Os Presidentes de Câmara comprometem-se a aprovar pelo menos um projecto de construção com emissões zero até 2025 e a apresentar um relatório anual sobre o progresso.
Comunicado de imprensa completo em: https://www.c40.org/press_releases/clean-construction-declaration-launch
Hannah Prime, Media and Editorial Manager
+44 (0) 776 939 7801
FONTE C40 Cities Climate Leadership Group
SOURCE C40 Cities Climate Leadership Group
Oslo, Los Angeles, Mexico et Budapest s’engagent à construire des bâtiments propres pour mener l’industrie du bâtiment vers un avenir durable
Dans la Clean Construction Declaration du C40, les maires s’engagent à révolutionner l’industrie mondiale de la construction et à la conduire vers un avenir plus durable afin de parvenir à “une vie prospère, résiliente et saine pour tous dans nos villes, en particulier pour nos communautés les plus vulnérables”.
L’industrie de la construction est actuellement responsable de plus de 23 % des émissions mondiales de GES et de 30 % de la consommation mondiale de ressources. „Business as usual” signifierait une dangereuse augmentation de la température mondiale de 3°C.
La déclaration fixe des objectifs audacieux et ambitieux pour développer les bâtiments et les infrastructures du futur avec des émissions nettes zéro :
- Réduire les émissions indirectes d’au moins 50 % pour tous les nouveaux bâtiments et les rénovations d’ici 2030
- Réduire les émissions indirectes d’au moins 50 % de tous les projets d’infrastructure d’ici 2030
- Acquisition et, si possible, utilisation de machines de construction exclusivement sans émissions à partir de 2025.
L’obligation de convertir et de moderniser le parc immobilier existant présente un énorme potentiel de création de nouveaux emplois verts – essentiel pour une récupération équilibrée et respectueuse de l’environnement à partir de COVID-19.
Les maires utiliseront leur pouvoir d’achat pour standardiser les équipements de construction à émission zéro, exiger la transparence et la responsabilité dans la chaîne d’approvisionnement, intégrer une politique de construction propre dans les procédures de conception, d’achat et de passation de marchés et dans les codes de construction. Les maires s’engagent à approuver au moins un projet emblématique de construction à émission zéro d’ici 2025 et à rendre compte chaque année des progrès réalisés.
Communiqué de presse complet à: https://www.c40.org/press_releases/clean-construction-declaration-launch
Hannah Prime, Media and Editorial Manager
+44 (0) 776 939 7801
SOURCE C40 Cities Climate Leadership Group
OMRON Strengthens Engagement with AliveCor with Series E Investment, Reinforces Cross-company Alliance for Remote Cardiovascular Condition Management
KYOTO, Japan, Nov. 24, 2020 /PRNewswire/ — OMRON Healthcare Co., Ltd. announced on November 24 additional investment into AliveCor by its parent company, OMRON Corporation, as part of $65 million series E funding for the leader in AI-based personal electrocardiogram (ECG) technology. OMRON led this round of investment, reinforcing the cross-company collaboration that began in 2017. The companies continue to build on their global alliance to accelerate development of solutions for cardiovascular disease management and remote patient monitoring utilizing ECG technology.
“OMRON is committed to developing life-saving cardiovascular health technologies in pursuit of our ‘Going for Zero’ vision to eliminate heart attacks and strokes. It is a lofty goal and, as we said when we evolved our vision, we cannot do it alone. That is why we seek like-minded partners, like AliveCor, to advance our initiatives and work together to save lives,” said Isao Ogino, president and CEO of OMRON Healthcare.
“Over one billion adults are hypertensive worldwide (*1), and their risk of stroke is nearly five times greater (*2) if they also suffer from Afib (atrial fibrillation). Hypertension is also an underlying health condition which increases the risk of complications with COVID-19 (*3). The ability to monitor both blood pressure and heart rhythm at home is essential for early detection, treatment and management of these cardiovascular health conditions.
“Our alliance with AliveCor will help enhance our current technology portfolio and provide hypertensive patients and healthcare professionals with data that can save lives–a complete picture of patients’ cardiovascular health that can be achieved with personal remote monitoring technology used at home. We continue to explore and develop new technologies to enhance the accessibility of home monitoring that help people to manage their condition, and will engage partners like AliveCor to ensure this technology is best-in-market, further accelerating our remote patient monitoring business to achieve our goal, Going for Zero,” said Ogino.
OMRON’s expanded investment into AliveCor builds upon the companies’ ongoing collaboration. OMRON expanded its blood pressure monitor portfolio with the launch of “Complete” (TM) the first blood pressure monitor with ECG capability in a single device and the first FDA-cleared technology developed in collaboration with AliveCor in 2019. Currently available in the U.S. at OmronHealthcare.com and participating retailers, expanded distribution of Complete (TM) is expected in other regions globally during the company’s fourth quarter.
(*1)World Health Organization: Hypertension ( https://www.who.int/news-room/fact-sheets/detail/hypertension )
(*2)American Heart Association: High Blood Pressure, AFib and Your Risk of Stroke
(*3)CDC: People with Certain Medical Conditions ( https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html )
About OMRON Healthcare
Committed to helping people live more active and fulfilling lives, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy. Throughout its history, OMRON has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in over 110 countries. OMRON provides the world’s No.1 blood pressure monitors and the company’s additional core categories are respiratory care, pain management and wellness products. The company also develops remote patient-monitoring service in the field of cardiovascular condition management.
SOURCE OMRON Healthcare Co., Ltd.
An ionic forcefield for nanoparticles: Tunable coating allows hitch-hiking nanoparticles to slip past the immune system to their target
Allay Their Fears WoW: How to Complete the Quest
The Rock Expresses Interest in Fortnite Skin Modeled on Him
Doublelift Retires: A Tale of Glory, Downfall, and Legacy
Native Fortnite Locations: How to Complete the Challenge
One-way street for electrons: Scientists observe directed energy transport between neighbouring molecules in a nanomaterial
Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research
Phytoplankton disturbed by nanoparticles: Due to its antibacterial properties, nanosilver is used in a wide range of products from textiles to cosmetics; but nanosilver if present at high concentrations also disrupts the metabolism of algae that are essential for the aquatic food
Russian scientists improve 3D printing technology for aerospace composites using oil waste
Pitt researchers create nanoscale slalom course for electrons: Professors from the Department of Physics and Astronomy have created a serpentine path for electrons
Original Content podcast: Just don’t watch Netflix’s ‘Holidate’ with your parents
XRI Launches Survey Examining Diversity & Inclusion Within XR Industry
Malta’s Pivots to Becoming a Fintech Haven
Black Friday on track for $8.9B+ in online sales as shoppers stay away from brick-and-mortar stores
Blockchain Voting is Possible: Dispelling Myths & Fears
Chinese Banks Suspend New Gold Trading Accounts Creation Amid Price Slump
Tony Hsieh, iconic Las Vegas tech entrepreneur, dies aged 46
NANO Rejected but Could Attempt Another Breakout Soon
How do Safe Online Sportsbooks Protect your Data?
OKEx Introduces One of Crypto’s Largest Loyalty Rewards Programs
Zoomlion begeistert auf der bauma China 2020 mit intelligenten Baumaschinen der nächsten Generation und sichert sich Aufträge im Wert von über 3 Milliarden USD
Ripple Is Cashing Out a Third of Its Stake in Surging MoneyGram
DreamHack Open November reaches playoffs
Zoomlion impressiona na Exposição bauma China 2020 com o lançamento de maquinários de construção inteligentes de última geração garantindo mais de US$ 3 bilhões em pedidos
mousesports move on to BLAST Premier Fall Showdown semis over Heroic
Zoomlion cautiva en la exposición bauma China 2020 con el lanzamiento de maquinaria de construcción inteligente de próxima generación que asegura más de 3 mil millones de dólares en pedidos
Insights on the Fatty Alcohol Global Market to 2026 – Featuring BASF, Ecogreen Oleochemicals & Godrej Industries Among Others
The Chemours Company Announces Completion of Private Offering of $800 Million Aggregate Principal Amount of 5.750% Senior Unsecured Notes Due 2028
Insights into Global High Voltage Switchgear Industries and Manufacturers to 2030 – by Equipment Type, Type of Use, Voltage Range and Customer Type
Zoomlion impressionne lors de la bauma China 2020 avec le lancement de machines de construction intelligentes de nouvelle génération lui permettant d’obtenir des commandes de plus de 3 G$
Energy5 days ago
ADAMA Mourns Death of Joe Krkoska, Executive Vice President of Global Operations
Blockchain1 week ago
Ethereum on a Tear as It Breaks New Yearly High
Blockchain1 week ago
Ethereum 2.0 Sees $10 Million Stake from Dubai-Based Investment Firm
Cyber Security1 week ago
Where Machine Learning Is Transforming Finance
Blockchain1 week ago
Bitcoin Begins to Stall After Parabolic Ascent
Blockchain1 week ago
Deutsche Bank Says Investors Increasingly Prefer Bitcoin Over Gold as Inflation Hedge
Energy6 days ago
Firmy Shanghai Electric a Siemens Energy založí Centrum na podporu rozvoje chytré energetiky (Smart Energy Empowerment Center)
Energy6 days ago
Trina Solar Purchases 1.2 Billion units of 210mm Monocrystal Silicon Wafers in Cooperation with Zhonghuan